Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Echinococcus granulosus | carboxylesterase 5A | 0.1626 | 1 | 1 |
Echinococcus multilocularis | carboxylesterase 5A | 0.1626 | 1 | 1 |
Echinococcus granulosus | acetylcholinesterase | 0.1626 | 1 | 1 |
Echinococcus multilocularis | glutamate (NMDA) receptor subunit | 0.0519 | 0.1601 | 0.1601 |
Schistosoma mansoni | glutamate receptor NMDA | 0.054 | 0.1765 | 0.0196 |
Schistosoma mansoni | family S9 non-peptidase homologue (S09 family) | 0.1626 | 1 | 1 |
Echinococcus granulosus | nmda type glutamate receptor | 0.038 | 0.0549 | 0.0549 |
Echinococcus multilocularis | acetylcholinesterase | 0.1626 | 1 | 1 |
Echinococcus granulosus | acetylcholinesterase | 0.1626 | 1 | 1 |
Brugia malayi | Carboxylesterase family protein | 0.1626 | 1 | 0.5 |
Echinococcus multilocularis | acetylcholinesterase | 0.1626 | 1 | 1 |
Loa Loa (eye worm) | carboxylesterase | 0.1626 | 1 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.1626 | 1 | 0.5 |
Loa Loa (eye worm) | acetylcholinesterase 1 | 0.1626 | 1 | 0.5 |
Echinococcus granulosus | glutamate NMDA receptor subunit | 0.0519 | 0.1601 | 0.1601 |
Echinococcus multilocularis | nmda type glutamate receptor | 0.038 | 0.0549 | 0.0549 |
Echinococcus granulosus | nmda type glutamate receptor | 0.0345 | 0.0282 | 0.0282 |
Echinococcus multilocularis | nmda type glutamate receptor | 0.0345 | 0.0282 | 0.0282 |
Loa Loa (eye worm) | hypothetical protein | 0.1626 | 1 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
AC3 (functional) | = 3.6 uM | Effect on DEVD cleavage by DEVDase assay with anti-Fas antibody treatment using Bcl-2 overexpressing HeLa cells; 3 fold activation concentration (AC3) | ChEMBL. | 11294384 |
AC3 (functional) | = 3.6 uM | Effect on DEVD cleavage by DEVDase assay with anti-Fas antibody treatment using Bcl-2 overexpressing HeLa cells; 3 fold activation concentration (AC3) | ChEMBL. | 11294384 |
AC3 (functional) | = 3.7 uM | Evaluated for HeLa cell viability with anti-Fas antibody treatment by XTT assay; 3 fold activation concentration (AC3) | ChEMBL. | 11294384 |
AC3 (functional) | = 3.7 uM | Evaluated for HeLa cell viability with anti-Fas antibody treatment by XTT assay; 3 fold activation concentration (AC3) | ChEMBL. | 11294384 |
AC3 (functional) | > 10 uM | Effect on DEVD cleavage by DEVDase assay without anti-Fas antibody using Bcl-2 overexpressing HeLa cells; 3 fold activation concentration (AC3) | ChEMBL. | 11294384 |
AC3 (functional) | > 10 uM | Evaluated for HeLa cell viability without anti-Fas antibody treatment by XTT assay; 3 fold activation concentration (AC3) | ChEMBL. | 11294384 |
AC3 (functional) | > 10 uM | Effect on DEVD cleavage by DEVDase assay without anti-Fas antibody using Bcl-2 overexpressing HeLa cells; 3 fold activation concentration (AC3) | ChEMBL. | 11294384 |
AC3 (functional) | > 10 uM | Evaluated for HeLa cell viability without anti-Fas antibody treatment by XTT assay; 3 fold activation concentration (AC3) | ChEMBL. | 11294384 |
MIC (functional) | > 50 ug ml-1 | Antibacterial activity was evaluated against Bacillus subtilis | ChEMBL. | 11294384 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.